By Sherri Oslick --
Immunomedics, Inc. of Morris Plains, NJ has been awarded U.S. Patent No. 7,282,567 ("Monoclonal antibody hPAM4," issued October 16, 2007) covering a humanized monoclonal antibody to a particular epitope in the MUC1 antigen expressed in most pancreatic cancers. The patent also covers therapeutic and diagnostic derivatives of hPAM4 for treating pancreatic cancer.
The newly issued patent covers Immunomedics' product Y-90 hPAM4, which is a yttrium-90-labeled hPAM4 currently in Phase I clinical trials. Y-90 hPAM4 has received Orphan Drug Status from the FDA.
The '567 patent issued from U.S. Application No. 10/461,885, which was filed on June 16, 2003 and which claims the benefit of U.S. Provisional Application No. 60/388,314, filed June 14, 2002. Independent claim 1 recites:
1. A humanized antibody or an antigen binding fragment thereof, comprising the complementarity-determining regions (CDRs) of a murine PAM4 monoclonal antibody (MAb) and the framework (FR) regions of the light and heavy chain variable regions of a human antibody and the light and heavy chain constant regions of a human antibody, wherein the CDRs of the light chain variable region of the humanized PAM4 Mab comprise CDR1 (SASSSVSSSYLY, SEQ ID NO:1); CDR2 (STSNLAS, SEQ ID NO:2); and CDR3 (HQWNRYPYT, SEQ ID NO:3); and the CDRs of the heavy chain variable region of the humanized PAM4 Mab comprise CDR1 (SYVLH, SEQ ID NO:4); CDR2 (YINPYNDGTQYNEKFKG, SEQ ID NO:5)and CDR3 (GFGGSYGFAY, SEQ ID NO:6), wherein said antibody or fragment thereof binds to a domain located between the amino terminus and the start of a repeat domain of MUC1.
Comments